Diagnosis, prognosis and therapeutic control of malignant diseases using PLA2R1 methylation analysis
The invention relates to the field of medicine, specifically to the diagnostics, prognosis and therapy control of tumour diseases. The invention is based on the hitherto unknown epigenetic silencing, discovered by chance by the inventors, of the phospholipase-A2-receptor-1-coding gene in leukaemia cells and in patients suffering from leukaemias and solid tumours. Based on this finding, the invention provides methods and a kit with which the degree of methylation of the phospholipase-A2-receptor-1 gene in an isolated sample of the patient is determined.
Property right: DE102010031354B3; WO002012007462A1
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Innovative 3D printed scaffolds offer new hope for bone healing
Researchers at the Institute for Bioengineering of Catalonia have developed novel 3D printed PLA-CaP scaffolds that promote blood vessel formation, ensuring better healing and regeneration of bone tissue. Bone is…
The surprising role of gut infection in Alzheimer’s disease
ASU- and Banner Alzheimer’s Institute-led study implicates link between a common virus and the disease, which travels from the gut to the brain and may be a target for antiviral…
Molecular gardening: New enzymes discovered for protein modification pruning
How deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children. Deubiquitinases (DUBs) are enzymes used by cells to trim protein…